We are live on ! Find out more
HQL

abrdn Life Sciences Investors

69 hedge funds and large institutions have $71.2M invested in abrdn Life Sciences Investors in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

114% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 14

42% more capital invested

Capital invested by funds: $50M → $71.2M (+$21.2M)

13% more funds holding

Funds holding: 6169 (+8)

3.4% more ownership

Funds ownership: 14.54%17.94% (+3.4%)

Holders
69
Holders Change
+8
Holders Change %
+13.11%
% of All Funds
1.36%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
14
Increased
30
Reduced
14
Closed
6
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q4 2019 in Review

69 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2019, worth a combined $71.2M — up 42% from $50M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new HQL positions and 6 closed out — a net gain of 8 holders — while 30 added to existing stakes and 14 trimmed.

The largest buyer was Karpus Investment Management, opening a new position worth an estimated $2.22M. The largest seller was Private Advisor Group, exiting entirely with an estimated $1.36M sold.

  • 69 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2019, up from 61 in Q3 2019.
  • Funds reported $71.2M of abrdn Life Sciences Investors stock for Q4 2019, up 42% quarter-over-quarter.
  • 14 funds opened new abrdn Life Sciences Investors positions in Q4 2019 and 6 closed out, a net change of +8 holders.
  • The largest abrdn Life Sciences Investors buyer in Q4 2019 was Karpus Investment Management, an estimated $2.22M added.
  • The largest abrdn Life Sciences Investors seller in Q4 2019 was Private Advisor Group, an estimated $1.36M sold.

Based on aggregated 13F filings for Q4 2019.